US FDA’s drug division chief resigns amid ethics concerns and lawsuit
Original source: https://www.investing.com/news/stock-market-news/us-fdas-drug-division-chief-resigns-amid-ethics-concerns-and-lawsuit-4327938
Read More »Neuraxis stock rises after FDA clearance for abdominal pain treatment
Original source: https://www.investing.com/news/stock-market-news/neuraxis-stock-rises-after-fda-clearance-for-abdominal-pain-treatment-93CH-4307803
Read More »Cogent Biosciences stock jumps after FDA grants breakthrough therapy status
Original source: https://www.investing.com/news/stock-market-news/cogent-biosciences-stock-jumps-after-fda-grants-breakthrough-therapy-status-93CH-4297373
Read More »FDA panel to weigh in on AI mental health devices
Original source: https://www.investing.com/news/stock-market-news/fda-panel-to-weigh-on-ai-mental-health-devices-4235808
Read More »Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency
Original source: https://www.investing.com/news/stock-market-news/vinay-prasad-returns-to-role-as-top-vaccine-regulator-at-fda-days-after-leaving-us-agency-4181651
Read More »FDA probes death of patient on Sarepta’s Elevidys, partner Roche says death unrelated to therapy
Original source: https://www.investing.com/news/stock-market-news/us-fda-investigates-third-death-after-treatment-with-sareptas-gene-therapy-elevidys-4153940
Read More »US FDA advisers recommend against Otsuka’s PTSD combination treatment
Original source: https://www.investing.com/news/stock-market-news/us-fda-advisers-vote-against-otsukas-ptsd-combination-treatment-4142478
Read More »Novo Nordisk cuts forecasts, shares rise ahead of FDA ban on Wegovy copycats
Original source: https://www.investing.com/news/stock-market-news/obesity-drugmaker-novo-nordisk-cuts-2025-outlook-posts-q1-profit-above-forecast-4027000
Read More »